Research & Development
Policy & Regulation
Trends & Finance
Stock: Page 2
Quotient to effect reverse stock split, regain Nasdaq compliance
Its ordinary shares are expected to begin trading on the Nasdaq composite on a split-adjusted basis on November 3.
October 31, 2022
Epigenetics testing firm Cardio Diagnostics goes public on Nasdaq
At the core of its cardiovascular solutions is the Integrated Genetic-Epigenetic Engine, developed at the University of Iowa.
October 26, 2022
OpGen closes $3.38M offering to support U.S. commercialization of molecular panel
The firm announced it has closed a $3.38 million registered direct offering with a single institutional investor.
October 4, 2022
Biosensor developer Know Labs goes public on the NYSE
After the close of trading Thursday, the company announced the pricing of an underwritten public offering of 3.6 million shares at $2.00 per share; it granted to the underwriter a 45-day option to purchase up to 540,000 additional shares at the same price.
September 15, 2022
BioAffinity Technologies goes public with $7.9M IPO
Gross proceeds from the offering are estimated to be about $7.9 million before deducting underwriting discounts and commissions and other estimated offering expenses.
August 31, 2022
Accelerate Diagnostics prices $35M stock offering
Its gross proceeds from the offering, before deductions, are expected to be $35 million, said Accelerate, a Tucson, AZ-based developer and supplier of identification and antimicrobial susceptibility tests (ID/AST) for bloodstream infections including sepsis.
August 18, 2022
LumiraDx Q2 revenues down 49% on drop in COVID testing
For the second quarter ended June 30, the London-based firm posted revenues of $44.7 million, compared to revenues of $87.2 million in Q2 2021, short of Wall Street analysts' average estimate of $53.1 million.
August 17, 2022
Agilent Technologies Q3 revenues rise 8%
For the fiscal third quarter ended July 31, Agilent's Life Sciences and Applied Markets Group posted revenues of $1.02 billion, a year-over-year increase of 14%; the CrossLab Group posted revenues of $359 million, a year-over-year increase of 5%; and the Diagnostics and Genomics Group posted revenues of $340 million, a year-over-year decrease of 2%.
August 16, 2022
Sophia Genetics revenues up 15% on platform volumes
The firm said that its year-over-year revenue growth on a constant currency basis, excluding COVID-19-related revenues, was 36%.
August 8, 2022
VolitionRx prices $6M public offering
The company said that gross proceeds to Volition from the offering are expected to be $6 million. Volition also granted the underwriter a 30-day option to purchase up to an additional 450,000 shares of its common stock at the public offering price. The offering is expected to close on or about August 2.
July 28, 2022
LumiraDx prices $75.3M public offering
Before deducting underwriting discounts and commissions and other offering expenses, the gross proceeds from the offering are expected to be approximately $75.3 million. The offering is expected to close on July 25.
July 20, 2022
Danaher Q2 diagnostics revenues rise 9%
For the quarter ended July 1, the company said its overall revenues, including revenues for its diagnostics, life sciences, and environmental and applied solutions divisions, rose 7% year-over-year to $7.75 billion from $7.22 billion, well ahead of Wall Street analysts' average estimate of $7.3 billion.
July 20, 2022
Page 2 of 3